AmpliChip CYP450 test: Personalized medicine has arrived in psychiatry

Jose De Leon

doi:10.1586/14737159.6.3.277

AmpliChip CYP450 test: Personalized medicine has arrived in psychiatry

Jose De Leon

Producción científica: Review article › revisión exhaustiva

108 Citas (Scopus)

Resumen

The US FDA has granted market approval for the first pharmacogenetic test using a DNA microarray, the AmpliChip CYP450, which genotypes cytochrome P450 (CYP)2D6 and CYP2C19. The test uses software to predict phenotypes and tests for 27 CYP2D6 alleles, including the deletions and duplications, and three CYP2C19 alleles. Other DNA microarray platforms are being developed for CYP testing, but none have been completely developed or approved by the FDA to date. The differences between an implementation of pharmacogenetic tests centered on the individual and implementation using a public health approach are discussed. In this review, the major obstacles to the wide implementation of pharmacogenetic testing in the clinical environment are summarized.

Idioma original	English
Páginas (desde-hasta)	277-286
Número de páginas	10
Publicación	Expert Review of Molecular Diagnostics
Volumen	6
N.º	3
DOI	https://doi.org/10.1586/14737159.6.3.277
Estado	Published - 2006

Nota bibliográfica

Funding Information:
Roche Molecular Systems, Inc. markets the AmpliChip CYP450 Test detecting the CYP2D6 and CYP2C19 gene variations. Roche Molecular Systems, Inc. supported four of Jose de Leon’s lectures, some equipment for his laboratory and an ongoing research-initiated grant. Jose de Leon has not received any consultant payments and has no other financial arrangements with Roche Molecular Systems, Inc. He has no stocks in Roche or Affymetrix. Additionally, in the past 2 years, Jose de Leon has been on the advisory board of Bristol-Myers Squibb; received researcher-initiated grants from Eli Lilly; and lectured supported by Eli Lilly (once) and by Bristol-Myers Squibb (once).

Financiación

Roche Molecular Systems, Inc. markets the AmpliChip CYP450 Test detecting the CYP2D6 and CYP2C19 gene variations. Roche Molecular Systems, Inc. supported four of Jose de Leon’s lectures, some equipment for his laboratory and an ongoing research-initiated grant. Jose de Leon has not received any consultant payments and has no other financial arrangements with Roche Molecular Systems, Inc. He has no stocks in Roche or Affymetrix. Additionally, in the past 2 years, Jose de Leon has been on the advisory board of Bristol-Myers Squibb; received researcher-initiated grants from Eli Lilly; and lectured supported by Eli Lilly (once) and by Bristol-Myers Squibb (once).

Financiadores
Bristol-Myers Squibb
Eli Lilly and Company

ODS de las Naciones Unidas

Este resultado contribuye a los siguientes Objetivos de Desarrollo Sostenible

Good health and well being

ASJC Scopus subject areas

Pathology and Forensic Medicine
Molecular Medicine
Molecular Biology
Genetics

Acceder al documento

10.1586/14737159.6.3.277

Otros archivos y enlaces

Citar esto

@article{3d59c0047f6b484a9239c8f12ccf0360,

title = "AmpliChip CYP450 test: Personalized medicine has arrived in psychiatry",

abstract = "The US FDA has granted market approval for the first pharmacogenetic test using a DNA microarray, the AmpliChip CYP450, which genotypes cytochrome P450 (CYP)2D6 and CYP2C19. The test uses software to predict phenotypes and tests for 27 CYP2D6 alleles, including the deletions and duplications, and three CYP2C19 alleles. Other DNA microarray platforms are being developed for CYP testing, but none have been completely developed or approved by the FDA to date. The differences between an implementation of pharmacogenetic tests centered on the individual and implementation using a public health approach are discussed. In this review, the major obstacles to the wide implementation of pharmacogenetic testing in the clinical environment are summarized.",

keywords = "Amplichip cyp450 test, Antidepressant, Antipsychotic, CYP2C19, CYP2D6, DNA microarray, Genotyping, Pharmacogenetics, Pharmacokinetics, Psychiatry",

author = "\{De Leon\}, Jose",

note = "Funding Information: Roche Molecular Systems, Inc. markets the AmpliChip CYP450 Test detecting the CYP2D6 and CYP2C19 gene variations. Roche Molecular Systems, Inc. supported four of Jose de Leon{\textquoteright}s lectures, some equipment for his laboratory and an ongoing research-initiated grant. Jose de Leon has not received any consultant payments and has no other financial arrangements with Roche Molecular Systems, Inc. He has no stocks in Roche or Affymetrix. Additionally, in the past 2 years, Jose de Leon has been on the advisory board of Bristol-Myers Squibb; received researcher-initiated grants from Eli Lilly; and lectured supported by Eli Lilly (once) and by Bristol-Myers Squibb (once).",

year = "2006",

doi = "10.1586/14737159.6.3.277",

language = "English",

volume = "6",

pages = "277--286",

number = "3",

}

TY - JOUR

T1 - AmpliChip CYP450 test

T2 - Personalized medicine has arrived in psychiatry

AU - De Leon, Jose

N1 - Funding Information: Roche Molecular Systems, Inc. markets the AmpliChip CYP450 Test detecting the CYP2D6 and CYP2C19 gene variations. Roche Molecular Systems, Inc. supported four of Jose de Leon’s lectures, some equipment for his laboratory and an ongoing research-initiated grant. Jose de Leon has not received any consultant payments and has no other financial arrangements with Roche Molecular Systems, Inc. He has no stocks in Roche or Affymetrix. Additionally, in the past 2 years, Jose de Leon has been on the advisory board of Bristol-Myers Squibb; received researcher-initiated grants from Eli Lilly; and lectured supported by Eli Lilly (once) and by Bristol-Myers Squibb (once).

PY - 2006

Y1 - 2006

N2 - The US FDA has granted market approval for the first pharmacogenetic test using a DNA microarray, the AmpliChip CYP450, which genotypes cytochrome P450 (CYP)2D6 and CYP2C19. The test uses software to predict phenotypes and tests for 27 CYP2D6 alleles, including the deletions and duplications, and three CYP2C19 alleles. Other DNA microarray platforms are being developed for CYP testing, but none have been completely developed or approved by the FDA to date. The differences between an implementation of pharmacogenetic tests centered on the individual and implementation using a public health approach are discussed. In this review, the major obstacles to the wide implementation of pharmacogenetic testing in the clinical environment are summarized.

AB - The US FDA has granted market approval for the first pharmacogenetic test using a DNA microarray, the AmpliChip CYP450, which genotypes cytochrome P450 (CYP)2D6 and CYP2C19. The test uses software to predict phenotypes and tests for 27 CYP2D6 alleles, including the deletions and duplications, and three CYP2C19 alleles. Other DNA microarray platforms are being developed for CYP testing, but none have been completely developed or approved by the FDA to date. The differences between an implementation of pharmacogenetic tests centered on the individual and implementation using a public health approach are discussed. In this review, the major obstacles to the wide implementation of pharmacogenetic testing in the clinical environment are summarized.

KW - Amplichip cyp450 test

KW - Antidepressant

KW - Antipsychotic

KW - CYP2C19

KW - CYP2D6

KW - DNA microarray

KW - Genotyping

KW - Pharmacogenetics

KW - Pharmacokinetics

KW - Psychiatry

UR - https://www.scopus.com/pages/publications/33745944880

UR - https://www.scopus.com/pages/publications/33745944880#tab=citedBy

U2 - 10.1586/14737159.6.3.277

DO - 10.1586/14737159.6.3.277

M3 - Review article

C2 - 16706732

AN - SCOPUS:33745944880

SN - 1473-7159

VL - 6

SP - 277

EP - 286

JO - Expert Review of Molecular Diagnostics

JF - Expert Review of Molecular Diagnostics

IS - 3

ER -

AmpliChip CYP450 test: Personalized medicine has arrived in psychiatry

Resumen

Nota bibliográfica

Financiación

ODS de las Naciones Unidas

ASJC Scopus subject areas

Acceder al documento

Otros archivos y enlaces

Huella

Citar esto